Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort.

Christof Aigner Martina GagglGunar StemerMichael Eder Georg A Böhmig Renate Kain Zoltán Proházka Nóra Garam Dorottya Csuka Raute Sunder-Plassmann Leah Charlotte Piggott Natalja Haninger-Vacariu Alice Schmidt Gere Sunder-Plaßmann

Published in: Journal of nephrology (2021)

In summary, eculizumab is the treatment of choice for cTMA patients that do not respond to plasma therapy. In patients with sTMA and C3G, the response rates to therapy are much lower and therefore, the decision to start therapy needs to be considered carefully.

Keyphrases

tertiary care
end stage renal disease
ejection fraction
stem cells
patient reported outcomes
combination therapy
smoking cessation